文献速递儿童青少年精神会诊联络精神医学

宫内暴露于哌甲酯、安非他明与托莫西汀及子代神经发育障碍:基于人群的队列研究与荟萃分析

In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders - a population-based cohort study and meta-analysis.
PubMed 文献 · Mol Psychiatry · 2025-03-27

基于瑞典登记库的队列研究纳入2008-2017年出生的861,650名儿童,比较妊娠期暴露于哌甲酯、安非他明或托莫西汀的儿童与母亲孕前停药儿童,未发现任何神经发育障碍、注意缺陷多动障碍或孤独症谱系障碍风险增加;荟萃分析合并丹麦研究后结果一致。

要点

  • 宫内暴露于注意缺陷多动障碍药物未增加子代任何神经发育障碍风险(校正HR 0.95,95%CI 0.82-1.11)。
  • 注意缺陷多动障碍(校正HR 0.92,95%CI 0.78-1.08)与孤独症谱系障碍(校正HR 0.86,95%CI 0.63-1.18)风险均未增加。
  • 荟萃分析合并丹麦研究后任何神经发育障碍汇总HR为1.00(95%CI 0.83-1.20)。

核心结论

  • 研究提供证据表明宫内暴露于注意缺陷多动障碍药物不增加子代长期神经发育障碍风险。
  • 研究重复了哌甲酯的安全性数据,并以安非他明和托莫西汀的新安全性数据加以扩展。
  • 这些发现对制定临床指南及帮助医疗提供者与孕妇做出知情决策至关重要。

研究设计与样本

  • 基于人群的队列研究,从瑞典登记库识别2008-2017年由572,731名母亲所生的861,650名儿童。
  • 暴露分类基于妊娠期 redeemed 药物,暴露儿童与母亲孕前停药儿童比较。
  • 主要结局为任何神经发育障碍,包括注意缺陷多动障碍和孤独症谱系障碍;采用Cox比例风险回归估计风险比,并校正母亲精神疾病与社会人口学因素。
  • 敏感性分析包括按药物类型、暴露时机与持续时间分层及同胞比较;另行荟萃分析合并本研究与既往丹麦研究数据。

主要发现

  • 任何神经发育障碍风险未增加(校正HR 0.95,95%CI 0.82-1.11)。
  • 注意缺陷多动障碍风险未增加(校正HR 0.92,95%CI 0.78-1.08)。
  • 孤独症谱系障碍风险未增加(校正HR 0.86,95%CI 0.63-1.18)。
  • 敏感性分析显示不同暴露持续时间、药物类型及同胞间均一致未见风险增加。
  • 荟萃分析支持上述发现(任何神经发育障碍汇总HR 1.00,95%CI 0.83-1.20)。

临床怎么用

  • 研究结论认为这些发现对制定临床指南及帮助医疗提供者与孕妇做出知情决策至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of Attention-Deficit/Hyperactivity Disorder (ADHD) medications during pregnancy is increasing, raising concerns about potential long-term effects on offspring. This study investigates in utero exposure to methylphenidate, amphetamines and atomoxetine and risk of offspring neurodevelopmental disorders (NDDs). The population-based cohort study identified from Swedish registers included 861,650 children born by 572,731 mothers from 2008-2017. We categorized exposure based on redeemed medication during pregnancy and compared exposed children to those whose mothers discontinued medication before conception. Main outcomes were any NDD, including ADHD and autism spectrum disorder (ASD). Cox proportional hazards regression estimated hazard ratios (HRs), adjusting for maternal psychiatric and sociodemographic factors. Sensitivity analyses included stratifications by medication type, timing, and duration of exposure, and sibling comparisons. We also performed a meta-analysis combining data from the present study with those from a previous Danish study. Results showed no increased risk for any NDD (HRadjusted 0.95, 95% CI 0.82-1.11), ADHD (HRadjusted 0.92, 95% CI 0.78-1.08), or ASD (HRadjusted 0.86, 95% CI 0.63-1.18). Sensitivity analyses showed consistent patterns of no increased risks across different exposure durations, medication types and between siblings. Meta-analyses further supported the findings (pooled HR for any NDD 1.00, 95% CI 0.83;1.20). Our study provides evidence that in utero exposure to ADHD medications does not increase the risk of long-term NDDs in offspring. This study replicates safety data for methylphenidate and extends it with new safety data on amphetamines and atomoxetine. These findings are crucial for informing clinical guidelines and helping healthcare providers and expectant mothers make informed decisions.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bang Madsen K, Larsson H, Skoglund C, et al. In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders - a population-based cohort study and meta-analysis. Mol Psychiatry. 2025. PMID: 40148550. doi:10.1038/s41380-025-02968-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。